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Background: Gefitinib, a tyrosine kinase inhibitor, is an effective treatment in advanced non-small cell lung cancer
(NSCLC) patients with an activating mutation in the epidermal growth factor receptor (EGFR). Randomised clinical
trials showed a benefit in progression free survival for gefitinib versus doublet chemotherapy regimens in patients
with an activated EGFR mutation (EGFR M+). From a patient perspective, progression free survival is important, but
so is health-related quality of life. Therefore, this analysis evaluates the Quality Adjusted progression free survival of
gefitinib versus three relevant doublet chemotherapies (gemcitabine/cisplatin (Gem/Cis); pemetrexed/cisplatin
(Pem/Cis); paclitaxel/carboplatin (Pac/Carb)) in a Dutch health care setting in patients with EGFR M+ stage IIIB/IV
NSCLC. This study uses progression free survival rather than overall survival for its time frame in order to better
compare the treatments and to account for the influence that subsequent treatment lines would have on overall
survival analysis.
Methods: Mean progression free survival for Pac/Carb was obtained by extrapolating the median progression free
survival as reported in the Iressa-Pan-Asia Study (IPASS). Data from a network meta-analysis was used to estimate
the mean progression free survival for therapies of interest relative to Pac/Carb. Adjustment for health-related
quality of life was done by incorporating utilities for the Dutch population, obtained by converting FACT-L data
(from IPASS) to utility values and multiplying these with the mean progression free survival for each treatment arm
to determine the Quality Adjusted progression free survival. Probabilistic sensitivity analysis was carried out to
determine 95% credibility intervals.
Results: The Quality Adjusted progression free survival (PFS) (mean, (95% credibility interval)) was 5.2 months (4.5;
5.8) for Gem/Cis, 5.3 months (4.6; 6.1) for Pem/Cis; 4.9 months (4.4; 5.5) for Pac/Carb and 8.3 (7.0; 9.9) for gefitinib.
Conclusions: In the Dutch health care setting, the previously established progression free survival benefit of
first-line gefitinib in advanced NSCLC EGFR M+ patients in comparison to standard doublet chemotherapy is further
supported by the Quality Adjusted PFS, which takes into account the additional health-related quality of life
benefits of gefitinib over doublet chemotherapy.
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Gefitinib is a selective small molecule inhibitor of the
epidermal growth factor receptor (EGFR) tyrosine kinase
(TK); it is an effective treatment for patients with
advanced non small cell lung cancer (NSCLC, stage IIIb/
IV, new TNM classification stage IV [1]) and activating
mutations of the EGFR TK [2-5].
The European Medicines Agency (EMA) approval for
gefitinib treatment in advanced NSCLC in patients with
EGFR mutation-positive (M+) tumours was based
largely on evidence from the Iressa Pan-Asia Study
(IPASS) [5], together with a comprehensive review of
gefitinib data in EGFR M+ NSCLC patients across lines
of therapy. In IPASS, a combination of paclitaxel and
carboplatin (Pac/Carb) was compared to gefitinib for
first-line treatment of clinically-selected advanced
NSCLC patients [5]. The pre-planned subgroup analysis
of the EGFR M+ patients in this study demonstrated
that gefitinib had a significantly longer progression free
survival (PFS) period than Pac/Carb (HR 0.48 (95%
Confidence Interval: 0.36; 0.64), median PFS 9.5 months
and 6.3 months, respectively [5,6]). Gefitinib was also
associated with a lower rate of common terminology
criteria (CTC) for grade 3 and 4 adverse events (AE)[5].
The PFS results and lower incidence of AE for gefitinib
were confirmed by other trials in EGFR M+ patients,
which compared either Pac/Carb [3] or other standard
doublet chemotherapies such as gemcitabine/cisplatin
(Gem/Cis) [7] or cisplatin/docetaxel [4] to gefitinib.
The increase in median PFS with gefitinib ranged from
1.8 [7] to 4.9 months [3].
Though the significant benefit in PFS was clear, there
did not appear to be a similar overall survival (OS) bene-
fit of gefitinib over doublet chemotherapy [3,4,7,8]. In
the IPASS, the median OS was 21.6 months for gefitinib
and 21.9 for Pac/Carb (p = 0.990)[8]. One reason for the
similar OS could be that all studies allowed for further
treatments at disease progression, including a cross-over
where patients on chemotherapy could cross-over to
gefitinib or another tyrosine kinase inhibitor (TKi) and
vice versa [3-5,7,8]. Second line therapy will affect OS;
this makes it difficult to interpret OS differences be-
tween initial treatments. Therefore, in this situation, PFS
may be considered a more appropriate measure of the
true effect of first-line treatment.
When considering treatment effect from a patient per-
spective, not only is the length of (progression free) sur-
vival important; health-related quality-of-life (HRQoL)
during that period is also important. HRQoL was mea-
sured with disease-specific HRQoL instruments in two
studies; IPASS used the FACT-L and First-SIGNAL used
the EORTC QLQ-C30 and QLQ-LC13. Both studies
demonstrated an improved HRQoL with gefitinib treat-
ment over doublet chemotherapies [5,7,9].It is important for a new drug to show added value in
comparison to standard care. QALYs are a recognised
and established measure of disease burden, including
both quantity-of-life (mean life-years) and quality-of-life,
and are therefore a useful means of expressing the value
of a new therapy. One measure of quality of life is
through the evaluation of utilities. Utility is a measure of
preference, and ranges from 0 (death) to 1 (full health).
How, then, should gefitinib be evaluated in compari-
son to standard care? Standard first-line care for
advanced NSCLC in the Netherlands is Gem/Cis or
pemetrexed/cisplatin (Pem/Cis) doublet chemotherapy
[10]. The CEGEDIM 2008 also reported first-line off
label prescription of TKi’s for advanced NSCLC [10].
While there is a lack of utility data for both gefitinib and
standard first-line doublet chemotherapies for advanced
NSCLC, the FACT-L data from the IPASS study can be
transformed into utility data using a published and
widely recognised algorithm [11]. Furthermore, a recent
Dutch study by Grutters et al. evaluated the utilities
among survivors of NSCLC [12] (predominantly stage I,
II and IIIa) and found that HRQoL in NSCLC patients is
influenced by the occurrence of adverse events and ob-
jective response.
The objective of this study is to evaluate the Quality
Adjusted PFS of gefitinib versus relevant doublet
chemotherapies in the Netherlands in patients with
EGFR M+ stage IIIb/IV NSCLC during the progression
free state.
Methods
When demonstrating the added value of a treatment, a
relevant time period should be used that covers all costs
and benefits for that disease. In oncology, a life time
horizon is often applied. However, in the NSCLC studies
used for this analysis, OS may be largely influenced by
the effect of subsequent treatment lines introduced at
disease progression. Therefore, this analysis measures
the true effect of gefitinib as a first line therapy by ex-
ploring preferences/utilities in a Dutch treatment con-
text during the progression free time frame.
Calculation of mean PFS for first-line therapy
In order to calculate the mean PFS for first-line therapy,
this analysis uses data from the gefitinib single technol-
ogy appraisal (STA) submission to the National Institute
for Health and Clinical Excellence (NICE) in the UK.
For this STA, a cost-effectiveness model was developed
to compare gefitinib to other doublet chemotherapies in
first-line treatment of EGFR M+ advanced NSCLC
patients [6]. To support this submission, in the absence
of a head-to-head trial, a network meta-analysis (NMA)
for all standard doublet chemotherapies for stage IIIb/IV
NSCLC relative to Pac/Carb [6] was performed to
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This NMA was based on a systematic literature search
performed in May 2009. In the same STA submission, a
meta-analysis was performed to estimate the relative
effects of gefitinib to Pac/Carb in EGFR M+ patients,
using data from the IPASS study [5] and the North East
Japan Study group trial [3,6]. The studies reported by
Mitsudomi et al. [4] and Lee et al. [7] were not used,
since they did not use Pac/Carb, but other doublet
chemotherapies. The NMA assumed that the relative
effect of chemotherapies is not influenced by EGFR
mutation status. Table 1 summarises the HRs for PFS
and odds ratios for objective response derived in the UK
NMA for all treatments of interest [6].
For an economic evaluation, the median PFS was
translated into a mean PFS. In order to calculate the
mean PFS for all treatments of interest, the HR from
Table 1 was applied to an estimated mean PFS for the
baseline therapy (Pac/Carb). The mean PFS for Pac/Carb
was obtained by extrapolating the median PFS as
reported in the IPASS study using a Weibull regression
model. In the Technical Support document 14 of DSU
about survival analysis [13], the Weibull distribution is
the most commonly used distribution within submis-
sions to NICE. The modelled Weibull curve showed a
good fit with the Kaplan Meier PFS curve (almost
complete overlap).
Calculation of utility data for the Netherlands
When estimating the preference for a certain health
state in the Netherlands, preferences provided by the
general Dutch public are needed. Hence, to assess the
utilities for Dutch advanced NSCLC EGFR M+ patients,
11 items of the FACT-L questionnaire data from the
subgroup of EGFR M+ patients (n = 261) in the progres-
sion free period in the IPASS study were converted into
Dutch utilities by applying the unequal distribution algo-
rithm published by Lamers et al. [11].
FACT-L data for each EGFR M+ patient from the
IPASS study were obtained for both arms at randomisa-
tion, at 1 week of treatment, and then at 3, 6, 9, 12, 15,
18, 24, 30, 36 and 42 weeks, up until progression of dis-
ease. For each patient, both the utility at each time point
and the change from baseline (CFB) were obtained. The
mean difference and standard deviation were calculated
and time points were weighted by the number of partici-
pants available at each time point. To calculate statisticalTable 1 HR, and odds ratios obtained with the NMA for durat
Pac/Carb Gem/C
PFS HR (95% CrI) 1 0.92 (0.
OR (Odds ratio) (95% CrI) 1 1.16 (0.
HR:Hazard ratio, PFS: progression free survival, OR: objective response Data retrieve
patient group with advanced NSCL and first-line treatment, ** determined for EGFRsignificance between utility CFB, an unpaired t-test was
used.
In the absence of data for all comparators, the utility
value calculated for Pac/Carb in the progression free
period in IPASS was also used for the other doublet
chemotherapies (Pem/Cis and Gem/Cis). This might
provide an underestimation of utility values for the other
doublet chemotherapies; the implications of this as-
sumption are explored in the discussion.Calculation of quality adjusted life years in PFS
To estimate the QALYs for the progression free period,
the treatment arm-specific utilities were multiplied with
the estimated mean PFS to calculate the Quality
Adjusted PFS for each treatment.
Since no other utility data for the Netherlands exists
we have compared our findings with the utilities used in
the model presented in the NICE STA submission [6].
These utilities are based on British preference weights.
The estimation of the utility during PFS from the NICE
STA consists of four components: stable baseline disease
(i.e. state of disease without any change in pre-treatment
condition), objective response, effect of drug administra-
tion, and effect of AE. Patients with stable disease have a
utility of 0.653 [14]; objective response gives an incre-
ment of 0.053 (mean of Nafees et al. [14] and Doyle
et al. [15]). The mode of administration of the drug also
influenced utility, with a decrement of 0.043 for intra-
venous therapy and 0.014 for oral therapy [16].
Adverse events lead to a decrement ranging from 0.03
for rash to 0.09 for neutropenia [14]; all adverse events
were set to occur in the first cycle.Results
Mean PFS for first-line therapy
Table 2 presents the mean PFS as calculated with the cost
effectiveness model for the three doublet chemotherapies
and gefitinib. Doublet chemotherapy results were
6.7 months for Pac/Carb (95% Credibility Interval (CrI):
5.9; 7.4), 7.0 months for Gem/Cis (95% CrI: 6.1; 7.9) and
7.2 months for Pem/Cis (95% CrI: 6.2; 8.2). The mean
PFS with gefitinib was 10.5 months (95% CrI: 8.9;
12.6). This was significantly higher than the doublet
chemotherapies and is in line with the HR of 0.43 for
gefitinib versus 0.92 for Gem/Cis and 0.88 for Pem/
Cis.ion of PFS and OR, all relative to Pac/Carb treatment
is* Pem/Cis* Gefitinib**
80; 1.04) 0.88 (0.74; 1.05) 0.43 (0.34; 0.53)
93; 1.44) 1.64 (1.15; 2.27) 4.63 (3.01; 6.98)
d from UK NMA [6] 95% CrI: 95% credibility interval, * determined for general
M+ patients.
Table 2 PFS and Quality Adjusted PFS (QA-PFS) in months (mean and 95% CrI)
Pac/Carb Gem/Cis Pem/Cis Gefitinib
PFS duration (months) 6.7 (5.9; 7.4) 7.0 (6.1; 7.9) 7.2 (6.2; 8.2) 10.5 (8.9; 12.6)
QA-PFS (months) 4.9 (4.4; 5.5) 5.2 (4.5; 5.8) 5.3 (4.6; 6.1) 8.3 (7.0; 9.9)
ΔQA-PFS with gefitinib (months) 3.4 (2.4; 4.8) 3.2 (2.0; 4.6) 3.0 (1.9; 4.4) -
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In the IPASS study used for utility data in this analysis,
251 of the 261 EGFR M+ patients completed the FACT-
L questionnaire at baseline, and at least once during
treatment in the progression free state. The baseline util-
ity was 0.736 ± 0.1059 for all EGFR M+ patients. At
baseline, no difference was present between the two
treatment arms. Figure 1 shows the utilities for both
treatment arms, together with the number of patients in
the progression free state at each time point (reflected
by bubble size). In the gefitinib arm, utility increased
after start of treatment; after 3 weeks, a steady state level
was reached. The number of patients in the progression
free state slowly declined from 128 at baseline and week
1 to 50 at week 42. The Pac/Carb arm showed a decline
in utility in the first week; thereafter, the utility increased
again and stabilised for the remainder of the progression
free period. Patient numbers in the progression free state
ranged from 123 at baseline and week 1 to 14 at week
42. At all time points in the progression free state, there
was a significant difference between the utilities of the
gefitinib and the doublet chemotherapy arms (unpaired
t-test P < 0.00001). The weighted mean for the CFB in
utilities associated with being treated with gefitinib was
0.0528 ± 0.0095; for Pac/Carb, this was 0.0011 ± 0.018.
Quality adjusted PFS
In order to obtain the Quality Adjusted PFS, the specific
utilities in each treatment arm were multiplied with the
estimated mean PFS to calculate the Quality Adjusted
PFS. The Quality Adjusted PFS was 4.9 months (95%















Figure 1 Utility per treatment arm during progression free state in IP
baseline (week number 0), both bubbles completely overlap.for Gem/Cis, 5.3 months (95% CrI: 4.6; 6.1) for Pem/Cis,
and 8.3 months (95% CrI: 7.0; 9.9) for gefitinib. This
resulted in a gain of Quality Adjusted PFS ranging be-
tween 3.0 and 3.4 months for gefitinib in comparison to
standard first-line treatments (doublet chemotherapies)
(Table 2).
When using the UK utilities from the NICE STA sub-
mission, comparable results were obtained. However,
baseline utility was lower, and therefore absolute gain in
Quality Adjusted PFS with gefitinib was lower (Table 3).
Regardless of which utilities were used, Quality Adjusted




In this study, we estimated the Quality Adjusted PFS for
patients with advanced NSCLC and EGFR M+ in the
Netherlands. The estimated mean PFS was significantly
longer with gefitinib than with standard doublet chemo-
therapy. Using Dutch preference weights from the
FACT-L in the EGFR M+ patients in the IPASS study
resulted in a baseline utility of 0.74. First-line treatment
with gefitinib results in a utility increment of 0.053. The
mean PFS in combination with the calculated utilities
resulted in a Quality Adjusted PFS of 8.3 months for
gefitinib compared to a range of 4.9 to 5.3 months for
the three doublet chemotherapies considered as com-
parators. This is a relative gain of  50% for PFS and a
relative gain of  60% for quality adjusted PFS, empha-
sising the better quality of life for patients treated with
gefitinib compared to doublet chemotherapy. These22 24 26 28 30 32 34 36 38 40 42 44
umber
gefitinib Pac/Carb
ASS in EGFR M+ patients. Bubble size reflects number of patients; at
Table 3 Outcomes for PFS and QA PFS in an alternative scenario with UK utilities (mean number of months and
95% CrI)
Pac/Carb Gem/Cis Pem/Cis Gefitinib
PFS (months) 6.7 (6.0; 7.4) 7.0 (6.1; 7.9) 7.2 (6.2; 8.2) 10.5 (8.9; 12.4)
QALY associated with duration of PFS (months) 4.4 (3.9; 4.8) 4.6 (4.0; 5.2) 4.7 (4.0; 5.4) 6.9 (5.8; 8.1)
QALY increment associated with objective response
in PFS
0.17 (0.13; 0.20) 0.19 (0.15; 0.24) 0.22 (0.17; 0.28) 0.39 (0.31; 0.49)
QALY adjustment due mode of administration −0.16 (−0.16; -0.15) −0.16 (−0.17; -0.15) −0.16 (−0.17; -0.15) −0.15 (−0.17; -0.12)
QALY decrement associated with adverse events
in PFS
−0.051 (−0.055; -0.047) −0.054 (−0.063; -0.045) −0.060 (−0.076; -0.046) −0.006 (−0.004; -0.007)
Total QA-PFS (months) 4.3 (3.8; 4.8) 4.5 (3.9; 5.2) 4.7 (4.0; 5.4) 7.1 (6.0; 8.4)
ΔQA-PFS with gefitinib (months) 2.8 (1.9; 3.9) 2.6 (1.6; 3.7) 2.4 (1.4; 3.6) -
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the time to FACT-L deterioration in the EGFR M+
patients in the gefitinib arm compared with the Pac/
Carb arm [9].
Merits and limitations of Quality Adjusted PFS
When assessing the value of a new drug in oncology, it
is generally recommended to look at the consequences
of that new drug treatment over a lifetime horizon. This
requires inclusion of all lines of treatment in a disease
and the use of OS as endpoint. However, using OS as an
endpoint has some drawbacks when illustrating the
value of a treatment, especially since OS is not always
clearly linked to first-line treatment when multiple treat-
ment lines can be given. The use of second and subse-
quent lines of treatment affects OS in both arms,
particularly when there is significant cross-over to the
alternative treatment. In this specific EGFR M+ patient
population, relatively high response rates were seen
when gefitinib was given as a second-line treatment [3].
However, the response to second-line chemotherapy
after gefitinib was lower than response to second-line
gefitinib after chemotherapy; in Maemondo et al., the
response rate to second-line chemotherapy was 28.8%,
while it was 58.8% for second-line gefitinib [3]. Because
there is little second-line treatment response data avail-
able from other RCTs, we could not fully analyse gefiti-
nib’s effect on OS while taking into account the presence
and type of second-line therapy.
If there is indeed a lower response to second-line treat-
ment for standard doublet chemotherapy than for second
line gefitinib, this might explain the lack of survival bene-
fit of first-line gefitinib versus standard doublet chemo-
therapy in the gefitinib studies, despite the clear benefit
in PFS for gefitinib [3-5]. Support for this assumption
can be found in the study by Rosell et al. [17]; erlotinib
(another TKi), had a similar response rate in EGFR M+
patients when used in first-line and second-line treat-
ment (73.5% (95% CI: 64.1; 81.2) and 67.4% (95% CI:
57.3; 76.0), respectively) [17]. Patients progressing afterfirst-line erlotinib and receiving second-line doublet
chemotherapy experienced a response rate of only 33%
[17]. The reported OS for patients treated with erlotinib
was similar for first and second-line treatment (28 and
27 months, respectively).
In economic evaluations, the lack of OS data for spe-
cific treatment arms requires a high amount of assump-
tions to be incorporated into the analysis, often by
assuming that different treatment sequences of first and
second line treatments result in a similar OS [18]. This
assumption weakens the value of the results of the OS
evaluation, since survival variables are highly influencing
these results.
If in the current model next to progression free time,
post progression time with the use of OS NMA [6] is
also taken into account, the increase in QALY is 0.22
(95% CrI: -0.06;0.54) resulting in a cost per QALY for a
lifetime horizon of 69,478€ (95% CrI: -148,134;42,191).
This large credibility interval due to the high uncertainty
rate makes it difficult to use this as a valid outcome.
Using PFS as a primary outcome in this field is becom-
ing more common. A recent first-line treatment trial
with bevacizumab in advanced NSCLC changed the pri-
mary outcome from OS to PFS [19]. Next to the possi-
bility of earlier publication, one major decision point
was the possible confounding of an OS endpoint by use
of second-line therapy [19]. As in our analysis, when OS
results were analysed, no OS benefit was found for beva-
cizumab despite the PFS benefit [20].
Other authors have discussed whether PFS data is ac-
ceptable to FDA and EMA (19) and have noted difficul-
ties in reconciling positive PFS results with the lack of
clear benefit in OS outcomes (20).
Clearly, in some analysis situations, using Quality
Adjusted PFS during the progression free stage is a vi-
able alternative to using QALYs and a life time horizon.
Limitations of this study
A possible limitation of this study is the use of the Pac/
Carb derived utility as a proxy for other doublet
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and in the NMA other doublet chemotherapies showed
a higher objective response. An objective response to
therapy results in an increase in utility [14,15]. In Table 3,
all components of the UK domains of the utility value in
the PFS are presented; the differences in objective
response are responsible for 0.06 months between Pac/
Carb and Pem/Cis. Considering the total difference be-
tween chemotherapy and gefitinib, such difference is
considered minimal.
The baseline utility value of the current study is com-
parable with the 0.73 utility value of Lamers et al. [11].
Baseline values reported in the UK for this patient group
are lower, with Nafees at 0.65 [14] and Doyle at 0.67
[15]. There are two possible reasons for this difference.
The NSCLC patient group for which Nafees et al. [14]
determined preference weights received second-line
treatment, i.e., they had progressed from their initial
chemotherapy and were possibly feeling sicker than
patients starting with first-line therapy. Another explan-
ation could be differences in preference weights between
the Dutch and British population [11].
When using country-specific preference weights to
calculate QA-PFS , the differences in QA-PFS between
treatment arms can differ in magnitude. This is clearly
visible in Tables 2 and 3 when looking at (total) QA-PFS
and ΔQA-PFS with gefitinib. The values of QA-PFS for
the various treatment arms differ between the calcula-
tions for the Netherlands and the UK. For instance,
(total) QA-PFS of gefitinib for the Netherlands is 8.3
(7.0; 9.9) months, whereas for the UK the QA-PFS is 7.1
(6.0; 8.4) months. Not only the absolute values of QA-
PFS per treatment arm are different, but also the relative
differences between treatment arms within one country
are different, as can be seen for ΔQA-PFS with gefitinib
for Pac/Carb: 3.4 (2.4; 4.8) months in the Dutch scenario
versus 2.8 (1.9; 3.9) months for the UK scenario. High-
lighting these differences emphasises the value of using
country-specific utility data in health economic analyses
and decision making.
Adverse events do influence utility. In NSCLC, decre-
ments for AE vary from 0.35 for severe AE (such as dys-
pnoea grade ≥3)[12], to decrements of 0.03 for rash, to a
range from 0.09 to 0.27 for neutropenia [14-16]. Pain,
cough and dyspnoea resulted in decrements of 0.04 to
0.069 [15].
However, since AEs do not last the whole progression
free period, their absolute impact is small. The different
AE profiles of the three comparator chemotherapies are
therefore not considered a major influence on Quality
Adjusted PFS, as is also shown with the small effect of
AE on outcome when we use actual AE data and the UK
utilities (see Table 3). Our calculations assume that AEs
are reflected in the FACT-L score; when looking at thechemotherapy arm, a utility decrement in the first week
of treatment can be seen, which returned to baseline
after 3 weeks. This could be due to the occurrence of
AE in the first week of chemotherapy.
Conclusions
In conclusion, the PFS benefit of first-line gefitinib in
advanced Dutch NSCLC EGFR M+ patients in compari-
son to doublet chemotherapy is further supported by the
calculation of Quality Adjusted-PFS in the Dutch health
care setting, which takes account of the additional
HRQoL benefits for gefitinib over doublet chemotherapy.
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